The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients

Elijovich, Fernando; Laffer, CL; Schiffrin, E. L.

doi:10.1038/sj.jhh.1000438

Cited by 13 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, in the present study, the antihypertensive effect on office and ambulatory BP of zofenopril and candesartan was similar or even better than that observed in previous studies, thus strengthening the relevance of our results (9)(10)(11)(20)(21)(22). In the only available study evaluating the effect of zofenopril on a full 24-h monitoring period, performed in a relatively small sample of elderly hypertensive patients (16 patients under zofenopril vs 47 of our study), 24-h DBP and SBP were reduced by 3% and 4% vs 6% and 6% of our study (11).…”

Section: Discussionsupporting

confidence: 88%

“…The early administration of zofenopril in patients with acute myocardial infarction attenuates the progression of the clinical symptoms of heart failure and its clinical consequences (4), even in case of patients with other associated clinical conditions like hypertension or diabetes (5,6). In patients with primary hypertension, zofenopril has been shown to be as effective as atenolol (9), hydrochlorothiazide (10) and lisinopril (11). However, there are no comparative data with angiotensin II antagonists, i.e.…”

Section: Introductionmentioning

confidence: 97%

“…Zofenopril calcium, a prodrug of the active compound zofenoprilat, is an ACE inhibitor that has been successfully and safely employed in the treatment of acute myocardial infarction (4)(5)(6), heart failure (7,8) and primary hypertension (9)(10)(11). The early administration of zofenopril in patients with acute myocardial infarction attenuates the progression of the clinical symptoms of heart failure and its clinical consequences (4), even in case of patients with other associated clinical conditions like hypertension or diabetes (5,6).…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

A similar 24‐h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients

2006

View full text Add to dashboard Cite

Objective. To compare the antihypertensive effect of treatment with zofenopril vs candesartan by office and ambulatory blood pressure (BP). Design and methods. Following a 2-week wash-out from previous treatment, 236 grade I-II primary hypertensive patients were randomized double-blind to 12 weeks treatment with zofenopril 30 mg or candesartan 8 mg od. After 4 weeks, treatment was doubled in responder non-normalized (office systolic BP>140 mmHg and office diastolic BP reduction >10 mmHg) or non-responder patients (office systolic BP>140 mmHg and office diastolic BP reduction v10 mmHg). Following a further 4 weeks, non-responder or non-normalized patients were withdrawn. Results. In the intention-to-treat population, office systolic BP and diastolic BP reductions after 12 weeks of treatment were similar between the two groups (zofenopril: 21¡11/15¡8 mmHg, n5114 vs C: 20¡11/15¡7 mmHg, n5122; p5NS). In the 163 patients of the per-protocol population, office BP dropped by 22¡11/15¡8 mmHg (zofenopril) and 20¡10/15¡7 mmHg (candesartan; p5NS). Also 24-h ambulatory BPs were equally reduced by zofenopril and candesartan ( 7¡13/5¡8 mmHg vs 7¡12/5¡8 mmHg; p5NS). The trough-to-peak ratio and smoothness index were not significantly different between zofenopril and candesartan. Tolerability of both drugs was good. Conclusions. Monotherapy with zofenopril and candesartan similarly reduced office and 24-h BPs. Since almost 90% of patients were normalized by either zofenopril or candesartan, this result supports the importance of considering low-or high-dose monotherapies as initial treatment for most hypertensive patients of mild degree.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

A similar 24‐h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients

2006

View full text Add to dashboard Cite

show abstract

“…Zofenopril is an ACE inhibitor that has been successfully and safely employed in the treatment of acute myocardial infarction (11)(12)(13), heart failure (14,15) and essential hypertension (16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure

2006

View full text Add to dashboard Cite

Objective. The effects of a 12-week double-blind randomized treatment with zofenopril (Z) 15, 30 or 60 mg or hydrochlorothiazide (HCTZ) 12.5 or 25 mg, on trough office (n5353) and 24-h blood pressure (BP, n5245) were compared with that of their combinations in essential hypertensive patients (95(diastolic or DBP(110 mmHg, 18-75 years). Design and methods. Rate of normalized (office DBPv90 mmHg) or responder (reduction>10 mmHg if office DBP>90 mmHg) patients, 24-h BP changes vs baseline and the smoothness index were calculated at the end of treatment. Results. Efficacy of Z+HCTZ was greater than that of individual treatments, with best results achieved under Z30+HCTZ12.5 mg (normalized: 57%; normalized+responder: 80%; 24-h BP changes: 9¡1/11¡2 mmHg; smoothness index: 1.6¡0.3/1.8¡0.4) or Z60+HCTZ12.5 mg (normalized: 79%; normalized+responder: 93%; 24-h BP changes: 9¡2/ 13¡2 mmHg; smoothness index: 1.9¡0.4/2.5¡0.7). Conclusions. Z+HCTZ combination is more effective than monotherapy in yielding a homogeneous BP control over the 24 h.

show abstract

“…Since its selective, long-acting ACE inhibitory activity, it appears beneficial and well tolerated for the treatment of a number of cardiovascular diseases (eg., acute myocardial infarction, [27][28][29] heart failure, [30,31] and essential hypertension [32][33][34].…”

Section: Discussionmentioning

confidence: 99%

Treatment of hypertension: mono-therapy versus [Zofenopril and Hydrochlorothiazide] combined therapy: A review

Crespi¹

2017

Clin Res Trials

View full text Add to dashboard Cite

The need of at least two antihypertensive drugs to achieve optimal blood pressure (BP) control in patients with hypertension appears more and more evident. In particular, the combination of the angiotensin-converting enzyme inhibitor zofenopril together with hydrochlorothiazide (diuretic) at the dose 30/12.5 mg/day respectively is now approved in Italy, France, Switzerland and Greece for the treatment of mild to moderate hypertension.The aim of this work is therefore to collect results from all available reports in order to analyse efficacy, safety and metabolic effects of such combined therapy versus Zofenopril alone. Efficacy and safety data were threfore assessed taking into account the number of subjects (weighted analysis).It emerges that in various clinical trials the combined therapy was significantly more effective in treating hypertension when comparing to mono-therapy with the further advantage of a safety profile. Therefore the combined therapy analysed here appears to be a positive improvement of the currently available therapy for patients with BP.

show abstract

The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients

Cited by 13 publications

References 11 publications

A similar 24‐h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients

A similar 24‐h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients

Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure

Treatment of hypertension: mono-therapy versus [Zofenopril and Hydrochlorothiazide] combined therapy: A review

Contact Info

Product

Resources

About